Hemoglobin levels lower, erythropoietin stimulating agent use higher, even for water lead levels below EPA threshold for regulatory action
Your search for ESKD returned 54 results
For patients with type 2 diabetes, intensive glucose control has long-term benefits for preventing end-stage kidney disease (ESKD), according to a study published online March 22 in Diabetes Care.
Psoriasis may be another risk factor for infectious complications in patients receiving dialysis, according to investigators.
Patients with end-stage kidney disease (ESKD) undergoing maintenance dialysis express a desire to exercise to regain energy and strength, but many report barriers to exercise.
In patients with IgA nephropathy, dapagliflozin significantly reduced the risk of CKD progression when added to ACEi/ARB therapy.
Although more research is needed, data suggest that the cardioprotective effect of direct oral anticoagulants may extend to patients with advanced CKD.
Investigators report results from a systematic review and meta-analysis of data from 23 randomized controlled trials involving 15,144 patients with anemia of CKD.
“We believe that the data actually suggest possible benefit for ESKD [end-stage kidney disease] with intensive glucose control, and remain inconclusive for intensive blood pressure control and fibrate use given the wide confidence intervals for the more reliable ESKD outcomes,” write the authors.
Study findings do not support initiation of uric acid-lowering therapy to prevent CKD.
The systematic review and meta-analysis included a broad range of patients with and without chronic kidney disease.